This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stanton, A. Search for Related Content PubMed PubMed Citation Articles by Stanton, A. Social Bookmarking                   What's this?

Review: Potential of renin inhibition in cardiovascular disease

Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, St Stephen's Green, Dublin 2, Ireland, astanton{at}rcsi.ie

Since renin catalyses the first and rate-limiting step of the renin-angiotensin system (RAS) cascade, interruption of the generation of angiotensin II (Ang II) by renin inhibitors at this highly specific initial step of the cascade has long been a therapeutic goal. The early development of renin inhibitors was hampered by problems with bioavailability and high costs of synthesis. However, more recently a potent non-peptidic inhibitor of renin, aliskiren, with acceptable oral bioavailability, has been synthesised. Aliskiren effectively reduces Ang II levels in normal volunteers and has been shown to lower blood pressure (BP) in patients with mild-to-moderate hypertension.

Renin inhibitors would be expected to have similar, but not identical effects to those of the established RAS antagonists. Due to the lack of effective alternative enzyme pathways, blockade of Ang II production may be more effective with renin inhibition than with angiotensin-converting enzyme (ACE) inhibition.

Furthermore, because renin has high specificity for only one substrate, angiotensinogen, side-effects would be expected to be less frequent. It is currently unclear whether blockade of Ang II type 1 (AT₁) receptors, leaving other Ang II receptors (AT₂, AT₃ and AT₄) unblocked, is preferable to the reduction in plasma and tissue Ang II levels achieved with either ACE or renin inhibition.

Pharmacological suppression of the RAS, through ACE inhibition, or blockade of AT₁, β-adrenoceptor or mineralocorticoid receptors, has been proven to reduce morbidity and mortality in patients with hypertension, diabetes mellitus, atherosclerosis, heart failure and nephropathy. While, to date, aliskiren has only been shown to reduce BP, it appears likely that orally-active renin inhibitors could prove useful in the management of a wide range of cardiovascular pathologies.

Key Words: renin • renin inhibition • renin angiotensin system • blood pressure • vascular disease • atherosclerosis

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 1, 6-10 (2003)
DOI: 10.3317/jraas.2003.008


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. O'Brien, J. Barton, J. Nussberger, D. Mulcahy, C. Jensen, P. Dicker, and A. Stanton Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker Hypertension, February 1, 2007; 49(2): 276 - 284. [Abstract] [Full Text] [PDF]

				A. H. Gradman, R. E. Schmieder, R. L. Lins, J. Nussberger, Y. Chiang, and M. P. Bedigian Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients Circulation, March 1, 2005; 111(8): 1012 - 1018. [Abstract] [Full Text] [PDF]